STOCK TITAN
  1. Home
  2. News
  3. BDSX

BIODESIX INC - BDSX STOCK NEWS

Welcome to our dedicated page for BIODESIX news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on BIODESIX stock.

Biodesix Inc (BDSX) delivers innovative diagnostic solutions through advanced blood-based testing for lung disease and oncology. This news hub provides investors and healthcare professionals with essential updates on corporate developments, clinical advancements, and strategic partnerships.

Access real-time updates on earnings announcements, FDA clearances, clinical trial results, and biopharmaceutical collaborations. Our curated collection ensures you stay informed about critical developments in molecular diagnostics and precision medicine without needing to track multiple sources.

Key updates include:

• Financial performance reports
• Diagnostic test approvals
• Research partnership announcements
• Clinical study outcomes

Bookmark this page for streamlined access to verified Biodesix news. Combine regular monitoring with in-depth analysis of how these developments impact the diagnostic solutions landscape.

News

Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting

Rhea-AI Summary
Biodesix, Inc. announces new data on the clinical utility and real-world impact of Nodify CDT and Nodify XL2 tests in managing lung nodules. The Nodify XL2 test shows a 74% reduction in invasive procedures on benign nodules. The Nodify CDT test improves PET/CT imaging in identifying malignant nodules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
conferences
-
News

Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer

Rhea-AI Summary
Biodesix, Inc. announces two abstracts to be presented at the International Association for the Study of Lung Cancer (IASLC) 2023 World Lung Conference on Lung Cancer (WCLC). The first abstract shows that the VeriStrat host immune classifier can predict response to immune checkpoint inhibitor (ICI) regimens in patients with advanced stage non-small cell lung cancer (NSCLC). The second abstract highlights the performance of a pre-surgical Risk of Recurrence test in identifying patients with a high probability of recurrence in early stage NSCLC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
none
-
News

Biodesix to Participate in Two Upcoming Investor Conferences in September

Rhea-AI Summary
Biodesix CEO to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
conferences
News

Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer

Rhea-AI Summary
Biodesix announces data demonstrating a 51% relative increase in cancer diagnosis rate for lung nodules with the use of Nodify XL2 test
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
none
-
News

Biodesix Announces Second Quarter 2023 Results and Highlights

Rhea-AI Summary
Biodesix, Inc. announces record-setting second quarter results with $11.4 million in revenue, a 58% increase YoY, and a gross profit margin of 73%. The company also raised $27.5 million in equity funding through a private placement. Biodesix continues to publish data supporting the value of their lung diagnostics tests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
earnings
-
News

Biodesix to Participate in the Canaccord Genuity 43rd Annual Growth Conference

Rhea-AI Summary
Biodesix CEO, Scott Hutton, will present and host investor meetings at the Canaccord Genuity 43rd Annual Growth Conference from August 7-10, 2023. The fireside chat will be webcast live and available for replay on Biodesix's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.17%
Tags
conferences
News

Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
conferences earnings
-
News

Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

Rhea-AI Summary
Biodesix, Inc. announced that the ORACLE study achieved the primary endpoint of a statistically significant change in the proportion of benign lung nodules managed by Nodify XL2® experiencing invasive procedures. The study showed that patients with benign nodules managed with the Nodify XL2 test were 74% less likely to undergo an unnecessary invasive procedure compared to the control group.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
clinical trial
-
News

Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services

Rhea-AI Summary
Biodesix, Inc. announced that the Nodify CDT Test has been designated as an Advanced Diagnostic Laboratory Test (ADLT) by CMS, effective June 30, 2023. The Nodify CDT test is used in combination with the Nodify XL2 test for lung cancer diagnosis and treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
none
News

Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.83%
Tags
none
Stock BDSX logo
BIODESIX INC

Nasdaq:BDSX

BDSX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

BDSX Stock Data

80.14M
68.04M
48.45%
40.21%
0.67%
Diagnostics & Research
Services-medical Laboratories
Link
United States
LOUISVILLE